Inhibitors, which occur in 20–30% of hemophilia A patients, can be eliminated with immune tolerance-induction (ITI) therapy in which the immune system is trained to tolerate FVIII concentrate by the repeated and frequent administration of FVIII over several months, or sometimes years (Schep et al., 2018). The gene discussed is F8; the disease is hemophilia A.